Kinnevik Results Presentation Deck
IN APRIL WE INVESTED USD 25M INTO ENVEDA BIOSCIENCES,
ADDING TO OUR EMERGING CLUSTER OF LIFE SCIENCES INVESTMENTS
■
I
■
Enveda
Enveda Biosciences is a Colorado-based biotech founded in 2019 by Viswa
Colluru, a PhD in cellular and molecular biology who joined our investee company
Recursion as an early employee in 2016
Plant Based Drug Discovery
Viswa left Recursion in 2019 to launch Enveda, and found early backing from the
founders at Recursion and the team behind our partner fund Dimension
In April we invested USD 25m into Enveda alongside a follow-on investment by
Dimension and other insiders
■
The company focuses on mining natural products (mostly plants) for drug
discovery. Nature has yielded a large share of past blockbuster drug successes
such as Aspirin and Metformin, but has suffered diminishing returns due in part to
our inability to understand its chemical make-up
Enveda uses novel machine learning techniques such as large language models,
metabolomics, and robotics to index nature's chemical space and annotate its
function for new drug discovery
Enveda's platform is multi-layered and IP-protected, generating a compounding,
proprietary dataset, and is attracting significant interest from pharma and biotech
partners
Enveda fits squarely into our emerging life sciences strategy expanding our
healthcare portfolio into accessing the current technology revolution in the
pharma industry
Enveda's Search Engine
New Drugs in a Dark Chemical Space
I want an @inflammasome inhibitor that is
not @cytotoxic that is available in the @brain that has
a @mass between 200-600.
CONTINUE >
Viswa Colluru, PhD
CEO & Founder
While at an early stage, we believe Enveda has the potential to become a truly big company over the next 5-10 years
7
KINNEVIKView entire presentation